Dr John Holt innovated two forms of radiowave therapy prior to his retirement in 2004. These two modalities (refer below) form the basis of comprehensive research currently being conducted by the Radiowave Therapy Research Institute:
- UHF/XRT: Exposure of a patient to radiowaves acting as a radiosensitising agent prior to low-dose, external-beam radiotherapy using x or y-rays (Holt 1975).
- GMI/UHF: The patient receives an intravenous dose of “glycolytic metabolic inhibitors” (GMI), these agents are to disrupt the metabolism of cancer cells immediately prior to exposure to radiowaves (Holt 1983).
Both modalities use radiowaves, which is energy in the radiofrequency (RF) spectrum. Dr Holt proposed that both modalities are effective at the specific frequency of 434 MHz (megahertz) in the UHF (ultra-high frequency) band. Radiowave therapy is not a microwave treatment and nor is any therapeutic affect hyperthermic.
The radiowave therapy currently provided by the Clinic is the GMI/UHF modality. It is a long term aim of the Clinic to provide both the above treatment modalities, however the UHF/XRT treatment is contingent upon outcomes of research currently being conducted by the Radiowave Therapy Research Institute. For more about the Institute research visit www.the-institute.com.au.